Rare condition

Lymphocytic hypereosinophilic syndrome

ORPHA:314970 ↗Clinical subtype

0

studies recruiting now

as of 7 Sept 2026

0

studies registered in total

as of 7 Sept 2026

0

countries with a recruiting site

as of 7 Sept 2026

None

recruiting study posted to date

among recruiting studies

Recruiting trials

No registered studies found for Lymphocytic hypereosinophilic syndrome.

ClinicalTrials.gov has no study listed under this name as of 7 Sept 2026. That can change, and there are other routes worth knowing about.

Keep watching

Get an email when a new Lymphocytic hypereosinophilic syndrome study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

About Lymphocytic hypereosinophilic syndrome

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.

Treatments being studied

2 approved treatments and 9 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Approved: ImatinibApproved: Mepolizumab (Bosatria)
Phase 3Depemokimab
Phase 3Prednisone (Cortan)
Phase 3Prednisolone (Cortalone)
Phase 3Benralizumab (Fasenra)
Phase 2Dexpramipexole
Phase 2Reslizumab (Cinqaero)
Phase 2Ruxolitinib (Jakavi)
Phase 2Dupilumab (Dupixent)

+ 1 more in development

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).